UNSPSC 51191926: Hydroxydecyl ubiquinone or idebenone

This classification denotes an antioxidant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HB6PN45W4J. European Medicines Agency schedules Idebenone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08114MIG. Idebenone generally arises in the molecular formula C19H30O5. The term 'idebenone' is an International Nomenclature of Cosmetic Ingredients designation. IDEBENONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Hydroxydecyl ubiquinone or idebenone bears US NLM identifiers UMLS ID C0123163 and NCI Concept Code C74158.

UNSPSC 51191926 Hydroxydecyl ubiquinone or idebenone is a Commodity code nominally covering specialized biochemical compounds, but the recent state and local opportunities posted under it show a significant mismatch: the code currently indexes unrelated water-treatment chemicals and pharmaceutical supply-chain procurement. The City of Meriden's July 2026 IFB for sodium bisulfite (B02715) is a straightforward municipal chemical supply for a water pollution control facility, while the Minnesota Multistate Cooperative Purchasing Alliance's January 2026 RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802) covers manufacturer-direct contracts distributed through authorized wholesalers to state and local health facilities across Minnesota and Oregon. The code shows little relevant recent activity aligned with its stated biochemical scope.

The geographic footprint spans Connecticut and the Upper Midwest (Minnesota with extension to Oregon), with issuing bodies limited to a municipal water utility and a regional cooperative purchasing vehicle. The Meriden solicitation closes July 29, 2026, with standard municipal insurance and bonding requirements typical of local government chemical supply contracts. The MMCAP RFP closed March 26, 2026, with awards effective July 1, 2026, requiring cGMP and Drug Supply Chain Security Act compliance, vendor relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), and performance penalties of $200 to $1,500 per violation. Neither opportunity directly addresses the code's nominal product category, suggesting the code's taxonomy assignment may require clarification with the issuing procurement offices.